AUSTIN, Texas, Aug. 29, 2013 /PRNewswire/ -- XBiotech announced today that Dr. Fabrizio Bonanni has joined the Company as a member of the Board of Directors. Dr. Bonanni joins XBiotech after stepping down from Amgen this year where he ended his tenure as that Company's most senior officer in charge of operations. At Amgen, Dr. Bonanni held the position of Executive Vice President of Operations from 2007-2012, and between 1999-2007 held Senior Vice President positions in charge of manufacturing, quality and regulatory compliance. Prior to Amgen, Dr. Bonanni held the position of Corporate Vice President of Regulatory and Clinical Affairs at Baxter International.
XBiotech claims to have established manufacturing technologies that realize a dramatic reduction in capital requirements, shorter lead times, simpler regulatory compliance and unprecedented production flexibility compared to the complex manufacturing systems used by industry today. The Company plans to use this technology to produce its new True Human™ antibody therapeutics, and also to enable a highly competitive biosimilar business.
Dr. Bonanni stated, "I admire XBiotech's commitment to bring novel therapies to seriously ill people and do so with a new approach to biotechnology, which has the promise of high quality, fast response times, and better affordability. I am excited at the opportunity to contribute to XBiotech's success."
John Simard, the Company's Chairman & CEO commented, "I am delighted to have Fabrizio join XBiotech's Board of Directors. For years Fabrizio delivered on the responsibility to maintain drug supply and navigate the complex regulatory environment for the world's preeminent biopharmaceutical company. I believe his experience and knowledge will serve as a great asset to our innovative programs. For Fabrizio to give his confidence and share in our vision is indeed gratifying."
XBiotech is leading the commercialization of biological therapies—including the discovery and development of True Human™ antibodies. The Company's lead product candidate—in Phase III clinical studies—is a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and reduce lead times for biological drugs, ushering in a new era for cost and development efficiency in the biopharmaceutical industry.